ClinicalTrials.gg
CompletedNCT01193153Updated Jan 5, 2015Results posted

A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder

A Phase 3 interventional study of Placebo and paliperidone palmitate in Schizoaffective Disorder, sponsored by Janssen Scientific Affairs, LLC. Completed at 84 sites in 8 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2015-01-05.

Sponsored by Janssen Scientific Affairs, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
667
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing paliperidone in Psychotic Disorders — 1 open to participants now, 1 under way, none of them phase 3. paliperidone · Psychotic Disorders.

Enrollment
Largest of 22
667 · median 189
Started
2010
with 1 other
Phase 3
6 of 22
none open now
Registered
10th of 22
by date
Lead sponsor
2 of 22
Janssen Scientific Affairs, LLC

Among the 22 studies testing paliperidone in Psychotic Disorders, this one has the largest enrollment, is one of 2 that started in 2010, is one of 6 in phase 3, and was the 10th registered.

Psychotic Disorders

1,589 studies on the registry are indexed under Psychotic Disorders; 281 are open to participants now.

Browse Psychotic Disorders studies →

Open to participants now

1 of the 22 studies testing paliperidone in Psychotic Disorders is open now. Recruiting first, the newest first:

About paliperidone

paliperidone: first FDA approval 2006 (INVEGA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing paliperidone in Psychotic Disorders, or all of them as a file.
02

Study summary

This study will evaluate the efficacy of paliperidone palmitate compared with placebo in the delay of relapse of the symptoms of schizoaffective disorder. This study will also assess the safety and tolerability of paliperidone palmitate in patients with schizoaffective disorder.

Read the detailed description

Schizoaffective disorder is a chronic illness and generally requires life-long treatment. To date however, no medication has been evaluated in the maintenance treatment of schizoaffective disorder. This is a randomized (study drug assigned by chance), double-blind (neither physician nor patient knows the name of the assigned drug), placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of paliperidone palmitate, as monotherapy or as an adjunct to mood stabilizers or antidepressants, relative to placebo in delaying the time to relapse in patients with schizoaffective disorder. This study explores the use of paliperidone palmitate either as monotherapy or as an adjunct to mood stabilizers or antidepressants (MS/AD) because both treatment approaches are commonly used in the clinical management of schizoaffective disorder. Patients with acute symptoms of schizoaffective disorder will be enrolled. The study will consist of 4 periods: an up to 7 days screening/tolerability period, a 13-week open-label flexible dose lead-in period, a 12-week open-label fixed dose stabilization period, and a 15 months double-blind relapse prevention period. Patients without previous exposure to paliperidone ER (Invega), paliperidone palmitate (Invega Sustenna), risperidone, or RISPERDAL CONSTA will be given 4 to 6 days of paliperidone ER 6mg/day for tolerability testing. Patients can continue their current antipsychotic regimen through Day -1 (the day before the start of the study period). During the open-label periods, all patients will be treated with paliperidone palmitate. An initial loading dose of 234 mg (150 mg eq.) of paliperidone palmitate will be given by deltoid injection followed by 156 mg (100 mg eq.) deltoid injection on Day 8. Starting on Day 36, injections may be administered in either the deltoid muscle or the gluteal muscle. Doses at Days 36, 64 and 92 may be increased or decreased within the range of 78 mg (50 mg eq.) and 234 mg (150 mg. eq.) as clinically indicated. Dose will be fixed (at Day 92 dose) during the 12-week stabilization period. Patients who meet pre-determined stabilization criteria will be eligible to enter the double-blind relapse prevention period and will be randomly assigned to either receive paliperidone palmitate (at the Day 92 dose) or placebo treatment. Patients will have intramuscular (i.m.) study drug injection and efficay and saftety evaluations performed every 4 weeks throughout the study. Efficacy will be evaluated during the study using a relapse assessment, the Positive and Negative Symptom Scale (PANSS), the Clinical Global Impression of Severity for Schizoaffective Disorder (CGI-S-SCA), the Personal and Social Performance Scale (PSP), the Young Mania Rating Scale (YMRS), and the Hamilton Rating Scale for Depression (HAM-D). Safety will be assessed throughout the study by monitoring of adverse events, clinical laboratory tests, electrocardiograms (ECGs), vital sign measurements (temperature, pulse, and blood pressure), weight, and the monitoring of extrapyramidal symptoms using the Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A). Suicidality will be assessed by the Columbia Suicide Severity Rating Scale (C-SSRS). A 10 milliliter pharmacogenomic blood sample (sample for DNA research) will be collected from patients who give separate written informed consent for this part of the study. Participation in pharmacogenomic research is optional. Blood samples will be taken from patients being treated with lithium or valproate for the measurement of blood lithium or valproate levels. Approximately 52 mL (31 mL for patients who are not receiving lithium or valproate) of whole blood will be collected during the study. All patients will receive paliperidone palmitate 78, 117, 156, 234 mg (50, 75, 100, or 150 mg eq.) monthly by i.m. injection for the the first 25 weeks of the study (open-label periods). During the 15-month double-blind relapse prevention period, one half of the patients will be randomized to paliperidone palmitate treatment (50, 75, 100, or 150 mg eq. monthly i.m. injection) and the other half of the patients will be randomized to monthly placebo injection.

03

Conditions studied

  • Schizoaffective Disorder

Browse trials for

Keywords

  • schizoaffective disorder
  • paliperidone palmitate
  • INVEGA SUSTENNA
  • schizoaffective disorder relapse prevention
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosis of schizoaffective disorder
  • Experiencing an acute exacerbation of psychotic symptoms
  • A score of >=4 on at least 3 of the following 7 PANSS items: Delusions (P1), Hallucinatory behavior (P3), Excitement (P4), Hostility (P7), Tension (G4), Uncooperativeness (G8), and Poor Impulse Control (G14)
  • A score of >=16 on YMRS and/or a score of >=16 on the HAM-D-21
  • Healthy based on physical examinations, (ECG), laboratory tests, medical history, and vital signs measurements

Exclusion criteria

Exclusion Criteria:

  • A primary active mental illness diagnosis other than schizoaffective disorder
  • Have attempted suicide within 12 months or are at imminent risk of suicide or violent behavior
  • Subjects with first episode of psychosis
  • Received electroconvulsive therapy in the past 3 months
  • History of to or intolerance of paliperidone, risperidone, or 20% Intralipid (placebo)
  • Received long-acting antipsychotic medication within 2 injection cycles
  • Received therapy with clozapine within 3 months
  • A history of neuroleptic malignant syndrome
  • Previous history of lack of response to antipsychotic medication
  • Subjects receiving therapy with antidepressants or mood stabilizers that has been initiated and/or changed in dose \<30 days prior to screening
  • Receiving therapy with carbamazepine
  • Receiving therapy with monoamine oxidase inhibitors
  • Pregnant, breast-feeding, or planning to become pregnant
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
667 participants (actual)

Study arms

  • Experimental
    001

    paliperidone palmitate 78 117 156 234 mg (50 75 100 or 150 mg eq.) monthly by i.m. injection for 15 months

    Drug: paliperidone palmitate

  • Placebo comparator
    002

    Placebo monthly by i.m. injection for 15 months

    Drug: Placebo

Interventions

  • DrugPlacebo

    monthly by i.m. injection for 15 months

  • 78, 117, 156, 234 mg (50, 75, 100, or 150 mg eq.) monthly by i.m. injection for 15 months

06

What researchers measure

Primary outcomes

  1. Double-blind: Percentage of Participants Who Experienced Relapse

    Relapse was defined as first occurrence of any 1 of following:psychiatric hospitalization due to worsening symptoms; any intervention employed to avert imminent hospitalization due to worsening symptoms or need for additional antipsychotic,antidepressants/mood stabilizing medication; deliberate self-injury,suicidal/homicidal ideation that is clinically significant as determined by investigator,or violent behavior resulting in clinically significant injury to another person or property damage; worsening of any 1 or more of 8 selected positive and negative syndrome scale(PANSS) items to a score of greater than or equal to (\>= 6) after randomization(if the score for the corresponding item was less than or equal to \[\<=\] 4 at randomization); worsening of certain other measures in specific ways at 2 consecutive visits. Relapse by subgroup of participants on monotherapy,adjunctive therapy to antidepressants/mood stabilizers,participants with psychotic symptoms/mood symptoms was examined.

    Time frame: Day 1 up to Month 15 of double blind relapse prevention period

Secondary outcomes

  1. Double-blind: Change From Baseline in Personal and Social Performance (PSP) Total Score at Week 64 (Total Mixed Model Repeated Measures [MMRM] Analysis of Covariance [ANCOVA])

    The PSP scale was designed to assess the degree of dysfunction a participant exhibits during a month prior to any visit within 4 domains of behavior: a) socially useful activities, b) personal and social relationships, c) self-care, and d) disturbing and aggressive behavior, each rated on 6-point scale (1=absent to 6=very severe). Total transformed score from 1 to 100 is generated from raw score based on clinical interpretation of scores generated in 4 areas of functioning. A score lying between 71 and 100 indicated a good functioning; one between 31 and 70 indicated varying degrees of difficulty, and a score of \<=30 indicated functioning so poor that participant required intensive supervision.

    Time frame: Baseline and Week 64 of double blind relapse prevention period

  2. Open-label: Change From Baseline in Personal and Social Performance (PSP) Total Score at Endpoint

    The PSP scale was designed to assess the degree of dysfunction a participant exhibits during a month prior to any visit within 4 domains of behavior: a) socially useful activities, b) personal and social relationships, c) self-care, and d) disturbing and aggressive behavior, each rated on 6-point scale (1=absent to 6=very severe). Total transformed score from 1 to 100 is generated from raw score based on clinical interpretation of scores generated in 4 areas of functioning. A score lying between 71 and 100 indicated a good functioning; one between 31 and 70 indicated varying degrees of difficulty, and a score of \<=30 indicated functioning so poor that participant required intensive supervision.

    Time frame: Baseline and Endpoint (Week 13/LOCF) in Open-label (OL) Lead-in period, Endpoint (Week 25/LOCF) in open-label stabilization period

  3. Double-blind: Change From Baseline in Personal and Social Performance (PSP) Total Score at Endpoint

    The PSP scale was designed to assess the degree of dysfunction a participant exhibits during a month prior to any visit within 4 domains of behavior: a) socially useful activities, b) personal and social relationships, c) self-care, and d) disturbing and aggressive behavior, each rated on 6-point scale (1=absent to 6=very severe). Total transformed score from 1 to 100 is generated from raw score based on clinical interpretation of scores generated in 4 areas of functioning. A score lying between 71 and 100 indicated a good functioning; one between 31 and 70 indicated varying degrees of difficulty, and a score of \<=30 indicated functioning so poor that participant required intensive supervision.

    Time frame: Baseline and Endpoint (Week 64/LOCF) in double-blind period

  4. Double-blind: Number of Participants With Personal and Social Performance (PSP) Categorical Scores

    The PSP scale was designed to assess the degree of dysfunction a participant exhibits during a month prior to any visit within 4 domains of behavior: a) socially useful activities, b) personal and social relationships, c) self-care, and d) disturbing and aggressive behavior, each rated on 6-point scale (1=absent to 6=very severe). Total transformed score from 1 to 100 is generated from raw score based on clinical interpretation of scores generated in 4 areas of functioning. Number of participants in each specific category; good functioning (PSP total score \>70), variable functioning (PSP total score between 31 and 70), and poor functioning (PSP total score \<=30) were assessed.

    Time frame: Baseline and Endpoint (Week 64/LOCF) in DB period

  5. Open-label: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Endpoint

    The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.

    Time frame: Baseline and Endpoint (Week 13/LOCF) in OL Lead-in period, Endpoint (Week 25/LOCF) in open-label stabilization period

  6. Double-blind: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Endpoint

    The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.

    Time frame: Baseline and Endpoint (Week 64/LOCF) in double-blind period

  7. Open-label: Change From Baseline in Hamilton Rating Scale for Depression (HAM-D-21) Total Score at Endpoint

    The HAM-D-21 is a 21-item, clinician-rated scale to evaluate depressed mood as well as the vegetative and cognitive symptoms of depression. The items are rated on a 5-point (0 to 4) scale. The 5-point scale items use a rating of 0 (absent), 1 (doubtful to mild), 2 (mild to moderate), 3 (moderate to severe), and 4 (very severe). A rating of 4 is usually reserved for extreme symptoms. The responses for all 21 items are summed to yield the HAM-D-21 total score that ranges from 0-63.

    Time frame: Baseline and Endpoint (Week 13/LOCF) in OL Lead-in period, Endpoint (Week 25/LOCF) in open-label stabilization period

  8. Double-blind: Change From Baseline in Hamilton Rating Scale for Depression (HAM-D-21) Total Score at Endpoint

    The HAM-D-21 is a 21-item, clinician-rated scale to evaluate depressed mood as well as the vegetative and cognitive symptoms of depression. The items are rated on a 5-point (0 to 4) scale. The 5-point scale items use a rating of 0 (absent), 1 (doubtful to mild), 2 (mild to moderate), 3 (moderate to severe), and 4 (very severe). A rating of 4 is usually reserved for extreme symptoms. The responses for all 21 items are summed to yield the HAM-D-21 total score that ranges from 0-63.

    Time frame: Baseline and Endpoint (Week 64/LOCF) in double-blind period

  9. Open-label: Change From Baseline in Young Mania Rating Scale (YMRS) Total Score at Endpoint

    The YMRS was designed to measure the severity of manic symptoms, to gauge the effect of treatment on mania severity, and to detect a return of manic symptoms (for example relapse or recurrence). YMRS is a checklist of 11 items that are ranked on a scale of 0 to 4 or 0 to 8. Seven of the items (elevated mood, increased motor activity, sexual interest, sleep, language-thought disorder, appearance, and insight) are ranked 0 to 4 and have descriptors associated with each severity level (that is, 0, 1, 2, 3, 4). Four of the items (irritability, speech, content, and disruptive-aggressive behavior) are scored 0 to 8 and have descriptors for every other increment (that is, 0, 2, 4, 6, 8). The item score is based on participant's report of his or her condition and clinician's behavioral observations during the interview, with emphasis on the latter. Higher scores indicate worsening. Responses are summed to yield YMRS total score ranging from 0 to 60.

    Time frame: Baseline and Endpoint (Week 13/LOCF) in OL Lead-in period, Endpoint (Week 25/LOCF) in open-label stabilization period

  10. Double-blind: Change From Baseline in Young Mania Rating Scale (YMRS) Total Score at Endpoint

    The YMRS was designed to measure the severity of manic symptoms, to gauge the effect of treatment on mania severity, and to detect a return of manic symptoms (for example relapse or recurrence). YMRS is a checklist of 11 items that are ranked on a scale of 0 to 4 or 0 to 8. Seven of the items (elevated mood, increased motor activity, sexual interest, sleep, language-thought disorder, appearance, and insight) are ranked 0 to 4 and have descriptors associated with each severity level (that is, 0, 1, 2, 3, 4). Four of the items (irritability, speech, content, and disruptive-aggressive behavior) are scored 0 to 8 and have descriptors for every other increment (that is, 0, 2, 4, 6, 8). The item score is based on participant's report of his or her condition and clinician's behavioral observations during the interview, with emphasis on the latter. Higher scores indicate worsening. Responses are summed to yield YMRS total score ranging from 0 to 60.

    Time frame: Baseline and Endpoint (Week 64/LOCF) in double-blind period

  11. Open-label: Change From Baseline in Clinical Global Impression - Severity Schizoaffective Scale (CGI-S-SCA) Overall Score at Endpoint

    The CGI-S-SCA is a syndrome-specific 7-point scale (from 1 indicating not ill to 7 indicating very severely ill) that includes an overall severity score as well as scores for the positive, negative, manic, and depressive domains of the illness. The CGI-S-SCA was used to assess the level of overall impairment, as well as that related to each domain, at the time of the visit and for the week prior to the visit".

    Time frame: Baseline and Endpoint (Week 13/LOCF) in OL Lead-in period, Endpoint (Week 25/LOCF) in open-label stabilization period

  12. Double-blind: Change From Baseline in Clinical Global Impression - Severity Schizoaffective Scale (CGI-S-SCA) Overall Score at Endpoint

    The CGI-S-SCA is a syndrome-specific 7-point scale (from 1 indicating not ill to 7 indicating very severely ill) that includes an overall severity score as well as scores for the positive, negative, manic, and depressive domains of the illness. The CGI-S-SCA was used to assess the level of overall impairment, as well as that related to each domain, at the time of the visit and for the week prior to the visit".

    Time frame: Baseline and Endpoint (Week 64/LOCF) in double-blind period

07

Results

Posted Jan 5, 2015

Participant flow

Open-label Lead in Period
Participant flow — Open-label Lead in Period
MilestonePaliperidone PalmitatePlacebo
Started6670
Completed4320
Not completed2350
Withdrew: Lost to follow-up320
Withdrew: Pregnancy10
Withdrew: Withdrawal by subject690
Withdrew: > 6 weeks between 2 study drug40
Withdrew: Other140
Withdrew: Subject failed stabilization criteria470
Withdrew: Adverse event410
Withdrew: Death10
Withdrew: Lack of efficacy260
Open-label Stabilization Period
Participant flow — Open-label Stabilization Period
MilestonePaliperidone PalmitatePlacebo
Started4320
Completed3340
Not completed980
Withdrew: Adverse event90
Withdrew: Death20
Withdrew: Lost to follow-up100
Withdrew: Lack of efficacy50
Withdrew: Withdrawal by subject290
Withdrew: Subject failed stabilization criteria350
Withdrew: Other80
Double Blind Relapse Prevention Period
Participant flow — Double Blind Relapse Prevention Period
MilestonePaliperidone PalmitatePlacebo
Started164170
Completed10065
Not completed64105
Withdrew: Other23
Withdrew: Adverse event123
Withdrew: Death20
Withdrew: Lost to follow-up29
Withdrew: Pregnancy10
Withdrew: Withdrawal by subject1930
Withdrew: Experienced relapse2557
Withdrew: > 6 weeks between 2 study drug13

Outcome measures

PrimaryDouble-blind: Percentage of Participants Who Experienced Relapse

Relapse was defined as first occurrence of any 1 of following:psychiatric hospitalization due to worsening symptoms; any intervention employed to avert imminent hospitalization due to worsening symptoms or need for additional antipsychotic,antidepressants/mood stabilizing medication; deliberate self-injury,suicidal/homicidal ideation that is clinically significant as determined by investigator,or violent behavior resulting in clinically significant injury to another person or property damage; worsening of any 1 or more of 8 selected positive and negative syndrome scale(PANSS) items to a score of greater than or equal to (\>= 6) after randomization(if the score for the corresponding item was less than or equal to \[\<=\] 4 at randomization); worsening of certain other measures in specific ways at 2 consecutive visits. Relapse by subgroup of participants on monotherapy,adjunctive therapy to antidepressants/mood stabilizers,participants with psychotic symptoms/mood symptoms was examined.

Time frame:
Day 1 up to Month 15 of double blind relapse prevention period
Reported as:
Number · percentage of participants
Double-blind: Percentage of Participants Who Experienced Relapse
percentage of participantsPaliperidone PalmitatePlacebo
All Participants (n=164, 170)15.2 (NA to NA)33.5 (NA to NA)
Monotherapy subset (n=78, 73)11.532.9
Adjunct therapy subset (n=86, 97)18.634.0
Psychotic Symptoms (n=164, 170)12.831.2
Mood Symptoms;Any Mood Symptoms (n=164, 170)11.028.2
Mood Symptoms;Manic (n=164, 170)3.09.4
Mood Symptoms;Depressive (n=164, 170)4.913.5
Mood Symptoms; Mixed (n=164, 170)3.05.3
Statistical analysis
  • Paliperidone Palmitate vs Placebo · Log Rank · p = <0.001 · Hazard ratio (hr): 2.49 · 95% CI 1.55 to 3.99
  • Paliperidone Palmitate vs Placebo · Regression, Cox · p = 0.002 · Hazard ratio (hr): 3.38 · 95% CI 1.57 to 7.28
  • Paliperidone Palmitate vs Placebo · Regression, Cox · p = 0.021 · Hazard ratio (hr): 2.03 · 95% CI 1.11 to 3.68
  • Paliperidone Palmitate vs Placebo · Regression, Cox · p = <0.001 · Hazard ratio (hr): 2.82 · 95% CI 1.70 to 4.67
  • Paliperidone Palmitate vs Placebo · Regression, Cox · p = <0.001 · Hazard ratio (hr): 2.93 · 95% CI 1.70 to 5.04
  • Paliperidone Palmitate vs Placebo · Regression, Cox · p = 0.012 · Hazard ratio (hr): 3.62 · 95% CI 1.32 to 9.89
  • Paliperidone Palmitate vs Placebo · Regression, Cox · p = 0.006 · Hazard ratio (hr): 3.12 · 95% CI 1.39 to 6.98
  • Paliperidone Palmitate vs Placebo · Regression, Cox · p = 0.238 · Hazard ratio (hr): 1.93 · 95% CI 0.65 to 5.78
SecondaryDouble-blind: Change From Baseline in Personal and Social Performance (PSP) Total Score at Week 64 (Total Mixed Model Repeated Measures [MMRM] Analysis of Covariance [ANCOVA])

The PSP scale was designed to assess the degree of dysfunction a participant exhibits during a month prior to any visit within 4 domains of behavior: a) socially useful activities, b) personal and social relationships, c) self-care, and d) disturbing and aggressive behavior, each rated on 6-point scale (1=absent to 6=very severe). Total transformed score from 1 to 100 is generated from raw score based on clinical interpretation of scores generated in 4 areas of functioning. A score lying between 71 and 100 indicated a good functioning; one between 31 and 70 indicated varying degrees of difficulty, and a score of \<=30 indicated functioning so poor that participant required intensive supervision.

Time frame:
Baseline and Week 64 of double blind relapse prevention period
Reported as:
Least squares mean · Units on a scale
Double-blind: Change From Baseline in Personal and Social Performance (PSP) Total Score at Week 64 (Total Mixed Model Repeated Measures [MMRM] Analysis of Covariance [ANCOVA])
Units on a scalePaliperidone PalmitatePlacebo
Baseline (n=164, 170)72.8 ± 0.8174.5 ± 0.81
Change at Week 64 (n=98, 65)2.0 ± 0.92-1.3 ± 1.03
Statistical analysis
  • Paliperidone Palmitate vs Placebo · MMRM ANCOVA · p = 0.014 (P-value based on change from DB baseline in PSP score and was analyzed using mixed-model repeated measures analysis of covariance based on observed data; within-participant repeated measures were modeled using an unstructured covariance matrix.) · Least square mean difference: 3.3 · 95% CI 0.68 to 5.95
SecondaryOpen-label: Change From Baseline in Personal and Social Performance (PSP) Total Score at Endpoint

The PSP scale was designed to assess the degree of dysfunction a participant exhibits during a month prior to any visit within 4 domains of behavior: a) socially useful activities, b) personal and social relationships, c) self-care, and d) disturbing and aggressive behavior, each rated on 6-point scale (1=absent to 6=very severe). Total transformed score from 1 to 100 is generated from raw score based on clinical interpretation of scores generated in 4 areas of functioning. A score lying between 71 and 100 indicated a good functioning; one between 31 and 70 indicated varying degrees of difficulty, and a score of \<=30 indicated functioning so poor that participant required intensive supervision.

Time frame:
Baseline and Endpoint (Week 13/LOCF) in Open-label (OL) Lead-in period, Endpoint (Week 25/LOCF) in open-label stabilization period
Reported as:
Mean · Units on a Scale
Open-label: Change From Baseline in Personal and Social Performance (PSP) Total Score at Endpoint
Units on a ScalePaliperidone PalmitatePlacebo
OL Lead-in Period:Baseline (n=667)51.4 ± 11.02—
OL Lead-in Period:Change at Endpoint (n=622)12.6 ± 13.71—
OL Stabilization Period:Change at Endpoint (n=622)13.8 ± 14.92—
SecondaryDouble-blind: Change From Baseline in Personal and Social Performance (PSP) Total Score at Endpoint

The PSP scale was designed to assess the degree of dysfunction a participant exhibits during a month prior to any visit within 4 domains of behavior: a) socially useful activities, b) personal and social relationships, c) self-care, and d) disturbing and aggressive behavior, each rated on 6-point scale (1=absent to 6=very severe). Total transformed score from 1 to 100 is generated from raw score based on clinical interpretation of scores generated in 4 areas of functioning. A score lying between 71 and 100 indicated a good functioning; one between 31 and 70 indicated varying degrees of difficulty, and a score of \<=30 indicated functioning so poor that participant required intensive supervision.

Time frame:
Baseline and Endpoint (Week 64/LOCF) in double-blind period
Reported as:
Least squares mean · Units on a Scale
Double-blind: Change From Baseline in Personal and Social Performance (PSP) Total Score at Endpoint
Units on a ScalePaliperidone PalmitatePlacebo
Double-blind: Baseline (n=164, 170)74.5 ± 0.8172.8 ± 0.81
Double-blind: Change at Endpoint (n=161,168)0.5 ± 1.15-4.1 ± 1.13
Statistical analysis
  • Paliperidone Palmitate vs Placebo · ANCOVA · p = <0.001 (Change at Endpoint (Week 64/LOCF)) · Least square mean difference: 4.5 · 95% CI 1.94 to 7.15
SecondaryDouble-blind: Number of Participants With Personal and Social Performance (PSP) Categorical Scores

The PSP scale was designed to assess the degree of dysfunction a participant exhibits during a month prior to any visit within 4 domains of behavior: a) socially useful activities, b) personal and social relationships, c) self-care, and d) disturbing and aggressive behavior, each rated on 6-point scale (1=absent to 6=very severe). Total transformed score from 1 to 100 is generated from raw score based on clinical interpretation of scores generated in 4 areas of functioning. Number of participants in each specific category; good functioning (PSP total score \>70), variable functioning (PSP total score between 31 and 70), and poor functioning (PSP total score \<=30) were assessed.

Time frame:
Baseline and Endpoint (Week 64/LOCF) in DB period
Reported as:
Number · participants
Double-blind: Number of Participants With Personal and Social Performance (PSP) Categorical Scores
participantsPaliperidone PalmitatePlacebo
Baseline: Poor (n=164, 170)00
Baseline: Variable (n=164, 170)6984
Baseline: Good (n=164, 170)9586
Endpoint: Poor (n=161, 168)14
Endpoint: Variable (n=161, 168)6595
Endpoint: Good (n=161, 168)9569
SecondaryOpen-label: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Endpoint

The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.

Time frame:
Baseline and Endpoint (Week 13/LOCF) in OL Lead-in period, Endpoint (Week 25/LOCF) in open-label stabilization period
Reported as:
Mean · Units on a scale
Open-label: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Endpoint
Units on a scalePaliperidone PalmitatePlacebo
OL Lead-in Period:Baseline (n=667)85.8 ± 12.76—
OL Lead-in Period:Change at Endpoint (n=653)-21.8 ± 16.39—
OL Stabilization Period:Change at Endpoint (n=653)-23.8 ± 18.30—
SecondaryDouble-blind: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Endpoint

The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.

Time frame:
Baseline and Endpoint (Week 64/LOCF) in double-blind period
Reported as:
Mean · Units on a scale
Double-blind: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Endpoint
Units on a scalePaliperidone PalmitatePlacebo
Double-blind: Baseline (n=164, 170)51.1 ± 9.5051.8 ± 9.47
Double-blind: Change at Endpoint (n=161, 168)0.5 ± 14.017.4 ± 18.53
SecondaryOpen-label: Change From Baseline in Hamilton Rating Scale for Depression (HAM-D-21) Total Score at Endpoint

The HAM-D-21 is a 21-item, clinician-rated scale to evaluate depressed mood as well as the vegetative and cognitive symptoms of depression. The items are rated on a 5-point (0 to 4) scale. The 5-point scale items use a rating of 0 (absent), 1 (doubtful to mild), 2 (mild to moderate), 3 (moderate to severe), and 4 (very severe). A rating of 4 is usually reserved for extreme symptoms. The responses for all 21 items are summed to yield the HAM-D-21 total score that ranges from 0-63.

Time frame:
Baseline and Endpoint (Week 13/LOCF) in OL Lead-in period, Endpoint (Week 25/LOCF) in open-label stabilization period
Reported as:
Mean · Units on a scale
Open-label: Change From Baseline in Hamilton Rating Scale for Depression (HAM-D-21) Total Score at Endpoint
Units on a scalePaliperidone PalmitatePlacebo
OL Lead-in Period:Baseline (n=667)20.4 ± 7.81—
OL Lead-in Period:Change at Endpoint (n=653)-9.7 ± 8.53—
OL Stabilization Period:Change at Endpoint (n=653)-9.9 ± 9.08—
SecondaryDouble-blind: Change From Baseline in Hamilton Rating Scale for Depression (HAM-D-21) Total Score at Endpoint

The HAM-D-21 is a 21-item, clinician-rated scale to evaluate depressed mood as well as the vegetative and cognitive symptoms of depression. The items are rated on a 5-point (0 to 4) scale. The 5-point scale items use a rating of 0 (absent), 1 (doubtful to mild), 2 (mild to moderate), 3 (moderate to severe), and 4 (very severe). A rating of 4 is usually reserved for extreme symptoms. The responses for all 21 items are summed to yield the HAM-D-21 total score that ranges from 0-63.

Time frame:
Baseline and Endpoint (Week 64/LOCF) in double-blind period
Reported as:
Mean · Units on a scale
Double-blind: Change From Baseline in Hamilton Rating Scale for Depression (HAM-D-21) Total Score at Endpoint
Units on a scalePaliperidone PalmitatePlacebo
Double-blind: Baseline (n=164, 170)5.7 ± 3.245.6 ± 3.32
Double-blind: Change at Endpoint (n=161, 168)0.8 ± 5.403.4 ± 7.42
SecondaryOpen-label: Change From Baseline in Young Mania Rating Scale (YMRS) Total Score at Endpoint

The YMRS was designed to measure the severity of manic symptoms, to gauge the effect of treatment on mania severity, and to detect a return of manic symptoms (for example relapse or recurrence). YMRS is a checklist of 11 items that are ranked on a scale of 0 to 4 or 0 to 8. Seven of the items (elevated mood, increased motor activity, sexual interest, sleep, language-thought disorder, appearance, and insight) are ranked 0 to 4 and have descriptors associated with each severity level (that is, 0, 1, 2, 3, 4). Four of the items (irritability, speech, content, and disruptive-aggressive behavior) are scored 0 to 8 and have descriptors for every other increment (that is, 0, 2, 4, 6, 8). The item score is based on participant's report of his or her condition and clinician's behavioral observations during the interview, with emphasis on the latter. Higher scores indicate worsening. Responses are summed to yield YMRS total score ranging from 0 to 60.

Time frame:
Baseline and Endpoint (Week 13/LOCF) in OL Lead-in period, Endpoint (Week 25/LOCF) in open-label stabilization period
Reported as:
Mean · Units on a scale
Open-label: Change From Baseline in Young Mania Rating Scale (YMRS) Total Score at Endpoint
Units on a scalePaliperidone PalmitatePlacebo
OL Lead-in Period:Baseline (n=667)18.6 ± 9.48—
OL Lead-in Period:Change at Endpoint (n=653)-9.9 ± 9.45—
OL Stabilization Period:Change at Endpoint (n=653)-10.5 ± 10.14—
SecondaryDouble-blind: Change From Baseline in Young Mania Rating Scale (YMRS) Total Score at Endpoint

The YMRS was designed to measure the severity of manic symptoms, to gauge the effect of treatment on mania severity, and to detect a return of manic symptoms (for example relapse or recurrence). YMRS is a checklist of 11 items that are ranked on a scale of 0 to 4 or 0 to 8. Seven of the items (elevated mood, increased motor activity, sexual interest, sleep, language-thought disorder, appearance, and insight) are ranked 0 to 4 and have descriptors associated with each severity level (that is, 0, 1, 2, 3, 4). Four of the items (irritability, speech, content, and disruptive-aggressive behavior) are scored 0 to 8 and have descriptors for every other increment (that is, 0, 2, 4, 6, 8). The item score is based on participant's report of his or her condition and clinician's behavioral observations during the interview, with emphasis on the latter. Higher scores indicate worsening. Responses are summed to yield YMRS total score ranging from 0 to 60.

Time frame:
Baseline and Endpoint (Week 64/LOCF) in double-blind period
Reported as:
Mean · Units on a scale
Double-blind: Change From Baseline in Young Mania Rating Scale (YMRS) Total Score at Endpoint
Units on a scalePaliperidone PalmitatePlacebo
Double-blind: Baseline (n=164, 170)4.4 ± 3.464.4 ± 3.40
Double-blind: Change at Endpoint (n=161,168)-0.1 ± 5.473.2 ± 7.21
SecondaryOpen-label: Change From Baseline in Clinical Global Impression - Severity Schizoaffective Scale (CGI-S-SCA) Overall Score at Endpoint

The CGI-S-SCA is a syndrome-specific 7-point scale (from 1 indicating not ill to 7 indicating very severely ill) that includes an overall severity score as well as scores for the positive, negative, manic, and depressive domains of the illness. The CGI-S-SCA was used to assess the level of overall impairment, as well as that related to each domain, at the time of the visit and for the week prior to the visit".

Time frame:
Baseline and Endpoint (Week 13/LOCF) in OL Lead-in period, Endpoint (Week 25/LOCF) in open-label stabilization period
Reported as:
Mean · Units on a scale
Open-label: Change From Baseline in Clinical Global Impression - Severity Schizoaffective Scale (CGI-S-SCA) Overall Score at Endpoint
Units on a scalePaliperidone PalmitatePlacebo
OL Lead-in Period:Baseline (n=667)4.4 ± 0.58—
OL Lead-in Period:Change at Endpoint (n=652)-1.3 ± 0.99—
OL Stabilization Period:Change at Endpoint (n=652)-1.3 ± 1.07—
SecondaryDouble-blind: Change From Baseline in Clinical Global Impression - Severity Schizoaffective Scale (CGI-S-SCA) Overall Score at Endpoint

The CGI-S-SCA is a syndrome-specific 7-point scale (from 1 indicating not ill to 7 indicating very severely ill) that includes an overall severity score as well as scores for the positive, negative, manic, and depressive domains of the illness. The CGI-S-SCA was used to assess the level of overall impairment, as well as that related to each domain, at the time of the visit and for the week prior to the visit".

Time frame:
Baseline and Endpoint (Week 64/LOCF) in double-blind period
Reported as:
Mean · Units on a scale
Double-blind: Change From Baseline in Clinical Global Impression - Severity Schizoaffective Scale (CGI-S-SCA) Overall Score at Endpoint
Units on a scalePaliperidone PalmitatePlacebo
Double-blind: Baseline (n=164, 170)2.4 ± 0.682.5 ± 0.69
Double-blind: Change at Endpoint (n=161,168)0.0 ± 1.020.4 ± 1.15

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Open Label - Paliperidone Palmitate—54/667 (8.1%)332/667 (49.8%)
Double Blind - Paliperidone Palmitate—9/164 (5.5%)79/164 (48.2%)
Double Blind - Placebo—16/170 (9.4%)62/170 (36.5%)
Most frequent serious events
Showing 10 of 40
Most frequent serious events
EventOpen Label - Paliperidone PalmitateDouble Blind - Paliperidone PalmitateDouble Blind - Placebo
Schizoaffective DisorderPsychiatric disorders16/6671/1647/170
Suicidal IdeationPsychiatric disorders15/6670/1642/170
DepressionPsychiatric disorders1/6672/1640/170
Psychotic DisorderPsychiatric disorders4/6672/1642/170
Cardiac Failure CongestiveCardiac disorders0/6671/1640/170
Congestive CardiomyopathyCardiac disorders0/6671/1640/170
Coronary Artery DiseaseCardiac disorders0/6671/1640/170
Gastrooesophageal Reflux DiseaseGastrointestinal disorders0/6671/1640/170
Chest PainGeneral disorders0/6671/1640/170
BronchitisInfections and infestations0/6671/1640/170
Most frequent other events
Showing 10 of 30
Most frequent other events
EventOpen Label - Paliperidone PalmitateDouble Blind - Paliperidone PalmitateDouble Blind - Placebo
AkathisiaNervous system disorders74/6675/1643/170
Injection Site PainGeneral disorders71/6671/1642/170
InsomniaPsychiatric disorders67/6678/16412/170
Weight IncreasedInvestigations57/66714/1648/170
ParkinsonismNervous system disorders43/6673/1643/170
NasopharyngitisInfections and infestations9/6679/1646/170
HeadacheNervous system disorders36/6679/1646/170
HyperprolactinaemiaEndocrine disorders9/6677/1642/170
Upper Respiratory Tract InfectionInfections and infestations14/6677/1644/170
PyrexiaGeneral disorders8/6676/1642/170

Baseline characteristics

Open-label (OL) intent-to-treat (ITT) analysis set included all participants who received at least 1 injection of open-label study drug.

Age, Continuous
Age, Continuous(years)Entire Study Population
Mean39.5 ± 10.70
Sex: Female, Male
Sex: Female, Male(Participants)Entire Study Population
Female310
Male357
08

Study locations

84 sites
  • Garden Grove, California, United States
  • Oakland, California, United States
  • Oceanside, California, United States
  • Pico Rivera, California, United States
  • Riverside, California, United States
  • San Diego, California, United States
  • Torrance, California, United States
  • Denver, Colorado, United States
  • Hollywood, Florida, United States
  • Maitland, Florida, United States
  • North Miami, Florida, United States
  • Tampa, Florida, United States
  • Atlanta, Georgia, United States
  • Marietta, Georgia, United States
  • Schamburg, Illinois, United States
  • Wichita, Kansas, United States
  • Flowood, Mississippi, United States
  • Creve Coeur, Missouri, United States
  • Cedarhurst, New York, United States
  • Staten Island, New York, United States
  • Charlotte, North Carolina, United States
  • Cleveland, Ohio, United States
  • Philadelphia, Pennsylvania, United States
  • Arlington, Texas, United States
  • Austin, Texas, United States
  • Dallas, Texas, United States
  • Irving, Texas, United States
  • San Antonio, Texas, United States
  • Pleven, Bulgaria
  • Plovdiv N/A, Bulgaria
  • Rousse, Bulgaria
  • Sofia, Bulgaria
  • Ahmedabad, India
  • Aurangabad, India
  • Chennai, India
  • Jaipur, India
  • Lucknow Gpo, India
  • Mangalore, India
  • Mysore, India
  • Nasik, India
  • Pune, India
  • Uttar Pradesh, India
  • Vadadora, India
  • Varanasi, India
  • Vijaywada, India
  • Alor Setar, Malaysia
  • Ipoh, Malaysia
  • Kota Bharu, Malaysia
  • Kota Kinabalu, Malaysia
  • Kuala Lumpur N/A, Malaysia
  • Kuala Lumpur, Malaysia
  • Tanjong Rambutan, Malaysia
  • Cebu, Philippines
  • Davao City, Philippines
  • Iloilo City, Philippines
  • Iloilo, Philippines
  • Quezon City, Philippines
  • Arad, Romania
  • Bucharest, Romania
  • Bucuresti, Romania
  • Cluj-Napoca, Romania
  • Cluj, Romania
  • Craiova, Romania
  • Oradea, Romania
  • Sibiu, Romania
  • Timisoara, Romania
  • Cape Town, South Africa
  • Centurion Gauteng, South Africa
  • Durban, South Africa
  • George, South Africa
  • Johannesburg, South Africa
  • Pretoria, South Africa
  • Tyger Valley, South Africa
  • Dnipropetrovsk, Ukraine
  • Donetsk, Ukraine
  • Glevakha, Ukraine
  • Ivano-Frankivsk, Ukraine
  • Kharkov, Ukraine
  • Kiev, Ukraine
  • Poltava, Ukraine
  • Simferopol, Ukraine
  • Uzhgorod, Ukraine
  • Village Stepanovka Kherson, Ukraine
  • Vinnitsa, Ukraine
09

References and documents

Publications

  • Alphs L, Fu DJ, Turkoz I. Paliperidone for the treatment of schizoaffective disorder. Expert Opin Pharmacother. 2016;17(6):871-83. doi: 10.1517/14656566.2016.1161029. Epub 2016 Mar 24. PubMed 26934062 ↗
  • Fu DJ, Turkoz I, Simonson RB, Walling DP, Schooler NR, Lindenmayer JP, Canuso CM, Alphs L. Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder. J Clin Psychiatry. 2015 Mar;76(3):253-62. doi: 10.4088/JCP.14m09416. PubMed 25562685 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2010, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2015, 1 year 3 months after primary completion. A results delay was requested in Jun 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2010
First posted
Sep 1, 2010
Start
Sep 2010
Primary completionActual
Oct 2013
CompletionActual
Oct 2013
Results delay requested
Jun 25, 2014
Results first posted
Jan 5, 2015
Last update
Jan 5, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01193153
Responsible party
Sponsor
First posted
Sep 1, 2010
Start date
Sep 2010
Primary completion
Oct 2013
Completion
Oct 2013
Results posted
Jan 5, 2015
Last update
Jan 5, 2015

Study contacts

Janssen Scientific Affairs, LLC Clinical Trial
study director · Janssen Scientific Affairs, LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paliperidone

Start the discussion